|  |  |
| --- | --- |
| DEPARTMENT OF HEALTH SERVICES Division of Care and Treatment Services  F-24277 (05/2024) | STATE OF WISCONSIN 42 CFR483.420(a)(2)  DHS 134.31(3)(o)  DHS 94.03 & 94.09  §§ 51.61(1)(g) & (h) |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| INFORMED CONSENT FOR MEDICATION Completion of this form is voluntary. If informed consent is not given, the medication cannot be administered without a court order unless in an emergency.  This consent is maintained in the client’s record and is accessible to authorized users. | | | | | | | | | |
| Name – Patient / Client (Last, First MI)       , | | | | | ID Number | | | Living Unit | Date of Birth |
| Name – Individual Preparing This Form | | | Name – Staff Contact | | | | | Name / Telephone Number – Institution | |
| MEDICATION CATEGORY | **MEDICATION** | | | | | RECOMMENDED **DAILY TOTAL DOSAGE RANGE** | | | ANTICIPATED DOSAGE RANGE |
| Antihistamine (sedative,  antianxiety) | - Atarax® (hydroxyzine hydrochloride)  - Vistaril® (oral, IM)  (hydroxyzine pamoate) | | | | | - Oral: 25 mg – 400 mg  - Injectable: 25 mg – 400 mg | | |  |
| The anticipated dosage range is to be individualized, may be above or below the recommended range but no medication will be administered without your informed and written consent. Recommended daily total dosage range of manufacturer, as stated in *Physician’s Desk Reference* (PDR) or another standard reference.  This medication will be administered  Orally  Injection  Other – Specify: | | | | | | | | | |
| Reason for Use of Psychotropic Medication and Benefits Expected (note if this is ‘Off-Label’ Use) Include DSM-5 diagnosis or the diagnostic impression (“working hypothesis”). | | | | | | | | | |
|  | | | | | | | | | |
| **2. Alternative mode(s) of treatment other than OR in addition to medications include** Note: Some of these would be applicable only in an inpatient environment. | | | | | | | | | |
| Environment and/or staff changes | | | | Rehabilitation treatments/therapy (OT, PT, AT) | | | | | |
| Positive redirection and staff interaction | | | | Treatment programs and approaches (habilitation) | | | | | |
| Individual and/or group therapy | | | | Use of behavior intervention techniques | | | | | |
| **Other Alternatives**: | | | | | | | | | |
| 3. Probable consequences of NOT receiving the proposed medication are | | | | | | | | | |
| Impairment of  Work Activities | | Family Relationships | | | | | Social Functioning | | |
|  | |  | | | | |  | | |
| Possible increase in symptoms leading to potential | | | |  | | | | | |
| Use of seclusion or restraint | | | | Limits on recreation and leisure activities | | | | | |
| Limits on access to possessions | | | | Intervention of law enforcement authorities | | | | | |
| Limits on personal freedoms | | | | Risk of harm to self or others | | | | | |
| Limit participation in treatment and activities | | | |  | | | | | |
| **Other Consequences**: | | | | | | | | | |
| Note: These consequences may vary depending upon whether or not the individual is in an inpatient setting. It is also possible that in unusual situations, little or no adverse consequences may occur if the medications are not administered. | | | | | | | | | |

| F-24277 | Medication: Atarax®, Vistaril® – (hydroxyzine) |
| --- | --- |
| Possible side effects, warnings, and cautions associated with this medication are listed below. This is not an all-inclusive list but is representative of items of potential clinical significance to you. For more information on this medication, you may consult further with your physician or refer to a standard text, such as the PDR. As part of monitoring some of these potential side effects, your physician may order laboratory or other tests. The treatment team will closely monitor individuals who are unable to readily communicate side effects in order to enhance care and treatment. | |
| Continued – Possible side effects, warnings, and cautions associated with this medication.Most Common Side Effects dry mouth, somnolence, injection site reaction | |
| **Less Common Side Effects** feeling clumsy, confused, or sleepy, congestion, constipation, blurry vision, changes in vision, difficult or  painful urination, fast, pounding heartbeat, increased sweating, indigestion, loss or gain of appetite, joint pain, muscle aching or cramping,  muscle stiffness, uncontrollable movement of the muscles, nausea, ringing or buzzing in ears, runny nose, stomach discomfort or pain,  tremor, unusual excitement, nervousness, restlessness, or irritability | |
| **Rare Side Effects** Although rare, please contact your doctor as soon as possible if any of the following side effects occur: severe abdominal or stomach pain; clay-colored stools or dark urine; severe diarrhea; difficulty swallowing; dizziness; fast or irregular heartbeat; fever; severe headache; hives; itching; prickly sensations; puffiness or swelling of the eyes, face, lips or tongue; redness of skin; seizures; shortness of breath; skin rash; tightness in chest; wheezing; severely sore throat; unusual bleeding or bruising; hallucinations. | |
| **Caution**  Precautions:  Hydroxyzine hydrochloride  Special populations (Beers Criteria): Avoid use in older adults due to strong anticholinergic effects and reduced clearance with advanced age, increasing the risk of anticholinergic effects and toxicity. Tolerance develops when used as a hypnotic. Avoid in patients with delirium or at high risk of delirium as it may induce or worsen delirium; in patients with a history of falls or fractures (unless safer alternatives are not available) as it may cause syncope, impaired psychomotor function or ataxia; in patients with dementia or cognitive impairment because of adverse CNS effects; and in men with lower urinary tract symptoms or benign prostatic hyperplasia as decreased urinary flow and urinary retention may occur. Avoid concomitant use of additional drugs with anticholinergic activity due to increased risk of falls, cognitive decline, and delirium. Elderly patients are at increased risk confusion and oversedation; dose reduction and monitoring recommended.  Hydroxyzine pamoate  Cardiovascular: QT prolongation and Torsade de Pointes have been reported with use; use with caution in patients with risk factors for QT prolongation, congenital or family history of long QT syndrome, recent myocardial infarction, uncompensated heart failure, bradyarrhythmias, concomitant use of drugs that are known to prolong the QT interval, and in other conditions that predispose patients to QT prolongation and ventricular arrythmia.  Concomitant use: Additive CNS depressant effects may occur with concomitant use of narcotics, non-narcotic analgesics, barbiturates, and alcohol; dosage reduction of CNS depressants recommended.  Dermatologic: Acute generalized exanthematous pustulosis has been reported; discontinue use if suspected and alternative therapy may be required.  Special populations (Beers Criteria): Avoid use in older adults due to strong anticholinergic effects and reduced clearance with advanced age, increasing the risk of anticholinergic effects and toxicity. Tolerance develops when used as a hypnotic. Avoid in patients with delirium or at high risk of delirium as it may induce or worsen delirium; in patients with a history of falls or fractures (unless safer alternatives are not available) as it may cause syncope, impaired psychomotor function or ataxia; in patients with dementia or cognitive impairment because of adverse CNS effects; and in men with lower urinary tract symptoms or benign prostatic hyperplasia as decreased urinary flow and urinary retention may occur. Avoid concomitant use of additional drugs with anticholinergic activity due to increased risk of falls, cognitive decline, and delirium. Confusion or over-sedation may occur in elderly patients; monitoring and dose reduction recommended. | |
| **Warning** | |
| **Syndrome Note** | |
| See standard reference text for an all-inclusive list of side effects. | |
| By my signature below, I GIVE consent for the named medication on Page 1 and anticipated dosage range. My signature also indicates that I understand the following:   1. I can refuse to give consent or can withdraw my consent at any time with written notification to the institution director or designee. This will not affect my right to change my decision at a later date. If I withdraw consent after a medication is started, I realize that the medication may not be discontinued immediately. Rather, it will be tapered as rapidly as medically safe and then discontinued so as to prevent an adverse medical consequence, such as seizures, due to rapid medication withdrawal. 2. Questions regarding this medication can be discussed with the Interdisciplinary Team, including the physician. The staff contact person can assist in making any necessary arrangements. 3. Questions regarding any behavior support plan or behavior intervention plan, which correspond with the use of the medication, can be directed to the client’s social worker, case manager, or psychologist. 4. I have the right to request a review at any time of my record, pursuant to § 51.30(4)(d) or § 51.30(5)(b). 5. I have a legal right to file a complaint if I feel that client rights have been inappropriately restricted. The client’s social worker, case manager, or agency/facility client rights specialist may be contacted for assistance. 6. My consent permits the dose to be changed within the **anticipated dosage range** without signing another consent. 7. I understand the reasons for the use of the medication, its potential risks and benefits, other alternative treatment(s), and the probable consequences that may occur if the proposed medication is not given. I have been given adequate time to study the information and find the information to be specific, accurate, and complete. 8. This medication consent is for a period effective immediately and not to exceed fifteen (15) months from the date of my signature. The need for and continued use of this medication will be reviewed at least quarterly by the Interdisciplinary Team. The goal, on behalf of the client, will be to arrive at and maintain the client at the minimum effective dose. | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **SIGNATURES** | | | | | **DATE SIGNED** |
| Client – If Presumed Competent to Consent/Parent of Minor/Guardian (POA-HC) | | | Relationship to Client  Self  Parent  Guardian (POA-HC) | |  |
| Staff Present at Oral Discussion | | | Title | |  |
| Client / Parent of Minor / Guardian (POA-HC) Comments | | | | | |
| **As parent/guardian (POA-HC) was not available for signature, he/she was verbally informed of the information in this consent.** | | | | |
| **Verbal Consent** | | | | |
| Obtained by – PRINT – Staff Name | Date Obtained | | Written Consent Received Yes  No | |
| Obtained from – PRINT – Parent / Guardian (POA-HC) Name | Date Expires | | Date Received | |